Skip to content

Sclerotherapy and Bone Marrow Injection In Aneurysmal Bone Cyst

Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05696834
Enrollment
20
Registered
2023-01-25
Start date
2023-03-01
Completion date
2025-12-31
Last updated
2023-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopedic Disorder

Brief summary

Aneurysmal bone cysts (ABCs) are benign, locally destructive growing bone tumors, which were first described in 1942 by Jaffé and Lichtenstein (1). They are most often diagnosed in childhood and early adulthood. The literature reports that ABCs comprise 1-6% of all primary benign bone tumors (2). Most cases of ABCs (75-90%) are reported for patients younger than 20 years, with a slightly higher incidence for females (3). Most common localizations are the pelvis, the metaphysis of long bones and the spine, but ABCs can also affect any other localization(2). ABCs that are associated with a preexisting osseous lesion are defined as secondary ABCs. They represent approximately 30% of all ABCs (2). Secondary ABCs can occur, e.g., in cases of a giant cell tumor, chondroblastoma or telangiectatic osteosarcoma

Detailed description

The clinical symptoms of an ABC are usually accidently discovered or may consist of pain and swelling in the affected region and pathological fractures ( complete and incomplete ) can be observed occasionally. In conventional radiography a relatively well-defined osteolytic, expansile lesion with possible blowout of the periosteum and a soap-bubble appearance can be found (4). MRI scanning shows cystic formations with typical fluid-fluid levels due to blood sedimentation (7). Because of the possible rapid growth with local destruction, the literature describes cases of ABCs that mimic malignant bone tumors

Interventions

PROCEDURESclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst

Sclerotherapy With Adjuvant Bone Marrow Injection In Management of Aneurysmal Bone Cyst

Sponsors

Al-Azhar University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum

Inclusion criteria

* All Patients above age of 1 year. * The affected area was all bones except skull, ribs, and other non-orthopedic specialties. * Primary or recurrent ABC * Incomplete Fractured affected bones as greenstick fracture. * Healed Pathological fracture without any surgical intervention

Exclusion criteria

* ABC. In skull, ribs, and other non-orthopedic specialties. * Age less than 1 year * Suspected malignancy or other bone cysts * Complete fractured bones and healed pathological fracture with surgical intervention.

Design outcomes

Primary

MeasureTime frameDescription
Healing1 yearResults will discuss in this study, according to assessment of ABC healing ( complete or not ) , and also following assessment of recurrence rate and incidence of complication.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026